Predicting the efficacy of COVID-19 convalescent plasma donor units with the Lumit Dx anti-receptor binding domain assay

BACKGROUND: The novel coronavirus SARS-CoV2 that causes COVID-19 has resulted in the death of more than 2.5 million people, but no cure exists. Although passive immunization with COVID-19 convalescent plasma (CCP) provides a safe and viable therapeutic option, the selection of optimal units for therapy in a timely fashion remains a barrier.

STUDY DESIGN AND METHODS: Since virus neutralization is a necessary characteristic of plasma that can benefit recipients, the neutralizing titers of plasma samples were measured using a retroviral-pseudotype assay. Binding antibody titers to the spike (S) protein were also determined by a clinically available serological assay (Ortho-Vitros total IG), and an in-house ELISA. The results of these assays were compared to a measurement of antibodies directed to the receptor binding domain (RBD) of the SARS-CoV2 S protein (Promega Lumit Dx).

RESULTS: All measures of antibodies were highly variable, but correlated, to different degrees, with each other. However, the anti-RBD antibodies correlated with viral neutralizing titers to a greater extent than the other antibody assays.

DISCUSSION: Our observations support the use of an anti-RBD assay such as the Lumit Dx assay, as an optimal predictor of the neutralization capability of CCP.

Errataetall:

UpdateOf: medRxiv. 2021 Mar 11;:. - PMID 33758874

Media Type:

Electronic Article

Year of Publication:

2021

Publication:

2021

Contained In:

To Main Record - volume:16

Contained In:

PloS one - 16(2021), 7 vom: 26., Seite e0253551

Language:

English

Contributors:

Janaka, Sanath Kumar [Author]
Clark, Natasha M [Author]
Evans, David T [Author]
Mou, Huihui [Author]
Farzan, Michael [Author]
Connor, Joseph P [Author]

Links:

Volltext

Keywords:

ACE2 protein, human
Angiotensin-Converting Enzyme 2
Antibodies, Neutralizing
Antibodies, Viral
EC 3.4.17.23
Immune Sera
Immunoglobulin G
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Spike Glycoprotein, Coronavirus
Spike protein, SARS-CoV-2

Notes:

Date Completed 06.08.2021

Date Revised 01.11.2023

published: Electronic-eCollection

UpdateOf: medRxiv. 2021 Mar 11;:. - PMID 33758874

Citation Status MEDLINE

doi:

10.1371/journal.pone.0253551

funding:

Supporting institution / Project title:

PPN (Catalogue-ID):

NLM328553921